An interventional study of MRSA nasal swab based de-escalation in Pneumonia, Bacterial, sponsored by University of Bari Aldo Moro. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by University of Bari Aldo Moro · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pneumonia, Bacterial with a site in Italy — 5 open to participants now, 5 under way, 1 of them phase 3. Pneumonia, Bacterial · Italy.
Among the 10 studies in Pneumonia, Bacterial with a site in Italy, this one is one of 2 that started in 2024, is the only one with no phase, and was the 6th registered.
153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.
Browse Pneumonia, Bacterial studies →5 of the 10 studies in Pneumonia, Bacterial with a site in Italy are open now. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy
Ages 18+
Infectopharm Arzneimittel GmbH · Sites in Italy, Austria, Germany and 2 more countries
Ages 18+
Wockhardt · Sites in Italy, Bosnia and Herzegovina, Bulgaria and 11 more countries
Ages 18–90
Policlinico Hospital · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 18 Pneumonia, Bacterial studies recruiting now, 12 (67%) set no upper age limit and 2 (11%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 76 is below the median of 132 across 107 interventional studies indexed under Pneumonia, Bacterial.
Median enrollment 232 across the 5 interventional studies, 300 across the 5 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 9 most frequent:
University of Bari Aldo Moro is the lead sponsor of 30 studies on the registry; 13 are open to participants now.
University of Bari Aldo Moro has 1 study filed under Pneumonia, Bacterial — fewer than ten, so there is no comparison to draw.
1 of the studies in Pneumonia, Bacterial with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06511583Azienda Ospedaliero-Universitaria CareggiFBS-ASaP: Fibrobronchoscopy in ASpiration Pneumonia in the Emergency Department | 2027-02-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Pneumonia, Bacterial with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current IDSA/ATS guidelines recommend Linezolid and Vancomycin for MRSA coverage in hospitalized patients with pneumonia, which is common clinical practice in Italy. However, a nasal PCR-assay for MRSA has a high negative predictive value and can facilitate rapid antibiotic de-escalation, thereby avoiding unnecessary anti-MRSA treatments. The indiscriminate use of these drugs has contributed to the emergence of resistant S. aureus strains and has led to significant adverse effects, without providing any survival benefits. Additionally, it has increased hospital stays and associated costs. The proposed study aims to use this diagnostic tool to shorten empirical anti-MRSA treatment duration in pneumonia patients, focusing on reducing antimicrobial therapy days while measuring in-hospital mortality, length of stay and adverse drug event incidence.
BACKGROUND On the basis of current IDSA/ATS guidelines antimicrobial agents such as Linezolid and Vancomycin are commonly used in hospitalized patients as an empirical treatment in community acquired pneumonias (CAPs) particularly in hospital-acquired pneumonias (HAPs) and ventilator associated pneumonias (VAPs), suggesting the empiric use of such anti-MRSA agents for patients with specific risk factors (e.g. recent hospitalization, exposure to parenteral antibiotics and/or previous isolation of these organisms, in particular from the respiratory tract) while obtaining culture data.
According to the 2023 annual report of the European Antibiotic Resistance Surveillance System (EARSS) there is a high prevalence of MRSA throughout the European territory, however, even in countries with high endemicity, the presence of MRSA has remained stable in the last years. In Italy, according to the National Antibiotic-Resistance Surveillance System AR-ISS, in 2021 the percentage of blood isolates MRSA isolates showed a reduction (29.9%) in the national territory, standing, however, at 33.6% in the Puglia region, a percentage higher than the European.
In patients with pneumonia, the nasal PCR-assay for MRSA has a high negative predictive value (NPV), with the crucial implication that a negative result can be used to guide the antibiotic de-escalation, avoiding an improper empiric use of the anti-MRSA therapy. Data supporting the clinical validity of the use of the nasal swab for MRSA as a diagnostic tool for pneumonia are robust, in this regard, as stated by the IDSA/ATS guidelines and supported by numerous retrospective studies, anti-MRSA treatment can be avoided in case of negative result, especially in non-severe CAP, thus preventing the misuse of anti-MRSA drugs.
The indiscriminate use of these drugs over time has considerably led to the selection of resistant strains of S. aureus such as Vancomycin-intermediate Staphylococcus aureus (VISA), heterogeneous VISA (hVISA) and Vancomycin-resistant Staphylococcus aureus (VRSA). Furthermore, the high risk of adverse events given by the empirical use of anti-MRSA drugs should also be noted including, among others, nephrotoxicity and ototoxicity with vancomycin and bone marrow suppression and peripheral neuropathy with linezolid, without a gain in terms of survival and with longer hospitalization stays.
In addition, the systematic use of such drugs is associated with an increase in hospital costs, where the PCR assay for MRSA has a relevant role. According to a study conducted by the Stanford University in 2021, enabling antibiotic de-escalation within 24h, its use has of facts led to a cost saving of vancomycin of $40.33 per patient.
On these assumptions, it is clear that using the nasal swab for MRSA in pneumonia diagnosis avoids the use of expensive drugs giving a large impact on health costs, while also reducing the risk of iatrogenic toxicity, hospital stay days and the duration of ventilation in VAPs.
The aim of our study is to implement the use of the nasal swab for MRSA as a diagnostic tool reducing the duration of the empirical anti-MRSA treatment in the population of hospitalized patients with pneumonia.
METHODS AND PROCEDURES. This will be a prospective, randomized single-center controlled study conducted in the Azienda Consorziale Policlinico di Bari.
The minimum sample size is 38 patients per group, for a total of 76 subjects, calculated assuming a standard deviation of 10, a power of 90% and a type I error of 5%.
The study will involve two phases: a first phase of enrollment of the subjects, with the collection of informed consent, of the anamnestic and personal data, a phase of randomization with consequent execution, within 48h from the start of the anti-MRSA empirical therapy, of the nasal swab for MRSA in the experimental group of patients. In a second step, the research assistants will continue the follow-up of the subject with cessation of the empiric treatment in case of negative result of the swab.
The implementation of these steps will be ensured by the performance of the tasks foreseen for each unit. Each clinical unit will:
For more precision, eligibility criteria and primary and secondary outcomes descriptions are fully detailed in the corresponding sections.
TIMELINE The research project will have a duration of 12 months following the approval of the Ethics Committee of the University of BarI.
STATISTICAL ANALYSIS The sample size is estimated based on the main outcome measure (duration of antibiotic intake), which the investigators assume to have an average of 10 days in the control group and 2 days in the experimental group. Assuming a standard deviation of 10, a power of 90%, and a type I error of 5%, it is necessary to enroll a minimum of 34 patients per group (thus a total of 68 patients) in order to demonstrate a reduction from 10 to 2 days in the duration of antibiotic intake. To this is added an estimated 10% of cases lost to follow-up, resulting in a final sample size of 76 patients.
The statistical analysis will be conducted according to the intention-to-treat approach. In case of contamination between the two treatment groups (which is considered unlikely in this case), an analysis per protocol will also be performed and the conclusions of the study will take into account the results of both. Numerical data will be summarized as mean and standard deviation, while categorical data as absolute and relative frequency. The two groups will be compared with the Student's t-test (numerical data) and with the Chi-Square test or Fisher's test (categorical data). The effects will be expressed as mean difference or relative risk, accompanied by a 95% confidence interval. All tests will be two-tailed, and a p-value lower than 0.05 will be considered significant. The statistical analysis will be carried out with R software version 4.3 (R Foundation for Statistical Computing, Vienna, Austria).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
Diagnostic Test: MRSA nasal swab based de-escalation
Patients randomized into the control arm will continue pneumonia treatment as per standard of care
Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
Duration of antibiotic intake
Time frame: From day zero to day 28
In-hospital mortality
Time frame: From day zero to day 28
Hospital lenght-of stay
Time frame: From day zero to day 28 or until discharge
Incidence of severe pneumonia requiring mechanical ventilation
Time frame: From day zero to day 28 or until discharge
Incidence of drug-related adverse outcomes
Time frame: From day zero to day 28
Hospital costs
Time frame: From day zero to day 28 or until discharge
Started May 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.
Of 19 interventional studies with no phase under Pneumonia, Bacterial, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Bari Aldo Moro